- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Luis E. Raez Discusses Goals for His Presidency of FLASCO
Luis E. Raez, MD, incoming president of the Florida Society of Clinical Oncology, provides an overview of his goals for his upcoming term.
Luis E. Raez, MD, incoming president of the Florida Society of Clinical Oncology, provides an overview of his goals for his upcoming term.
Transcript:
What are some of your goals as the incoming president of FLASCO?
As a new president of FLASCO, we have several goals. We are working with 12 industry partners in statewide projects that benefit cancer therapy outcomes and patients. For example, one of the projects I love the most because I’m a lung cancer doctor is lung cancer screening. Statewide we only screen 5% of all the patients that are at risk of having lung cancer. It is our goal to increase significantly that proportion. So that is one of the important projects that we have. We have other projects regarding access to drugs, payment of drugs, healthcare outcomes [and] most of these projects involve patient care and quality care.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
February 18th 2025Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).
Read More
